IM Therapeutics is building an HLA-directed platform for new therapies. They have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

Biotechnology

IM Therapeutics

IM Therapeutics' headquarters in Woburn, MA, United States

Peter Gottlieb

Aaron Michels

David Alleva, PhD

Ed Orr

Howard L. Weiner

Betty Diamond

Jay Skyler

Steven St. Peter

Jonathan Rigby

Jason R. Dinges

Edwin Liu

The Advisory Team at IM Therapeutics plays a crucial role in guiding the company's strategic direction and therapeutic development. Comprised of experienced advisors, the team leverages their expertise in autoimmune diseases and HLA biology to provide insights on clinical trial design, regulatory pathways, and market opportunities, ensuring that the company's innovations are both scientifically sound and commercially viable.

Advisory Team

The Leadership Team at IM Therapeutics drives the strategic vision and operational execution of the company's HLA-directed therapeutic platform. Comprising experts in scientific research and medical practice, including co-founders and executives, the team collaborates to advance innovative therapies for autoimmune diseases, ensuring alignment between research initiatives and clinical development. Their collective leadership fosters an environment of scientific excellence and facilitates partnerships that propel the company’s growth and impact in the field of type 1 diabetes and beyond.

IM Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

IM Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

Related companies